To satisfy antitrust regulators, the companies will sell products -- mostly cattle and small-animal vaccines and some animal-health pharmaceuticals -- to Boehringer Ingelheim. The German drugmaker is also getting research and manufacturing facilities from Wyeth's Fort Dodge Animal Health division as part of the deal.
Pfizer and Wyeth didn't disclose the price, but considering that it was less than 10% of the animal-health revenue from the combined company, the price probably doesn't matter that much. What's important for investors is that they're one step closer to closing the deal in the fourth quarter and getting on with the integration of the two companies.
Pfizer isn't the only one that's had to adjust its animal-health products to get its acquisition done. In July, Merck
Bayer, Eli Lilly
But let's not get ahead of ourselves -- first the companies have to get these deals closed.